78 FR 207 pg. 64017 - Manufacturer of Controlled Substances; Notice of Application; Cambrex Charles City, Inc.
Type: NOTICEVolume: 78Number: 207Page: 64017
Page: 64017FR document: [FR Doc. 2013-25091 Filed 10-24-13; 8:45 am]
Agency: Justice Department
Sub Agency: Drug Enforcement Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application; Cambrex Charles City, Inc.
Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 25, 2013, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:
| Drug | Schedule |
|---|---|
| Gamma Hydroxybutyric Acid (2010) | I |
| Amphetamine (1100) | II |
| Lisdexamfetamine (1205) | II |
| Methylphenidate (1724) | II |
| 4-Anilino-N-phenethyl-4-piperidine (8333) | II |
| Phenylacetone (8501) | II |
| Cocaine (9041) | II |
| Codeine (9050) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Hydrocodone (9193) | II |
| Methadone (9250) | II |
| Morphine (9300) | II |
| Oripavine (9330) | II |
| Thebaine (9333) | II |
| Opium, raw (9600) | II |
| Opium extracts (9610) | II |
| Opium fluid extract (9620) | II |
| Opium tincture (9630) | II |
| Opium, powdered (9639) | II |
| Opium, granulated (9640) | II |
| Oxymorphone (9652) | II |
| Noroxymorphone (9668) | II |
| Poppy Straw Concentrate (9670) | II |
| Alfentanil (9737) | II |
| Remifentanil (9739) | II |
| Sufentanil (9740) | II |
| Fentanyl (9801) | II |
The company plans to manufacture the listed controlled substances in bulk for sale to its customers, for dosage form development, for clinical trials, and for use in stability qualification studies.
Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 24, 2013.
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 2013-25091 Filed 10-24-13; 8:45 am]
BILLING CODE 4410-09-P